Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia
- Author:
- No author available
- Journal Title:
- Chinese Journal of Obstetrics and Gynecology
- Issue:
- 9
- DOI:
- 10.3760/cma.j.cn112141-20220628-00419
- Key Word:
- 子宫内膜肿瘤;子宫内膜增生;保留生育能力;基因组学;治疗结果;Endometrial neoplasms;Endometrial hyperplasia;Fertility preservation;Genomics;Treatment outcome
Abstract： Objective:To investigate the molecular classification of endometrial carcinoma (EC) and atypical endometrial hyperplasia (AEH) treated with fertility-sparing therapy, and to analyze its relationship with clinicopathological factors and treatment efficacy.Methods:A total of 46 EC and AEH patients who received fertility-sparing therapy and molecular classification tested by next generation sequencing in Peking University People's Hospital from June 2020 to December 2021, were retrospectively collected. The relationships between molecular classification and clinicopathological factors and treatment outcomes were analyzed.Results:(1) Of the 46 patients, including 40 EC and 6 AEH patients, 32 cases (71%, 32/45) had complete response (CR) after treatment, with median CR time of 8 months, 6 cases (13%, 6/45) had partial response, and 8 cases (25%, 8/32) had recurrence. (2) The cases were distributed as no specific molecular profile (NSMP) 34 cases (74%, 34/46) subtype mainly, high microsatellite instability (MSI-H) 7 cases (15%, 7/46), POLE ultra-mutated 3 cases (7%, 3/46), and copy number high (CNH) 2 cases (4%, 2/46). Patients with CNH had the hightest serum cancer antigen 125 (CA 125) level [(34.3±35.2) kU/L]. MSI-H subtype had more family history of tumors (6/7), more with loss of mismatch repair (MMR) protein expression by immunohistochemical (7/7), and higher nuclear antigen associated with cell proliferation (Ki-67) expression level (3/3). (3) Patients in MSI-H subgroup had the lowest CR rate at 6 months (0/6; P=0.019), and survival analysis showed that they were less likely to achieve CR than those with NSMP subtype ( P=0.022). Subgroup analysis of patients with NSMP showed that age ≥30 years related with longer treatment time to CR ( P=0.010). In addition, CR was obtained after treatment in 2/3 POLE ultra-mutated cases and 2/2 CNH, respectively. Conclusions:Molecular classification relates with the treatment response in patients with EC and AEH treated with fertility-sparing therapy. Patients with MSI-H subtype have poor treatment efficacy, and patients with NSMP need to be further studied and predict treatment benefit. However, there are few cases in POLE ultra-mutated and CNH subtypes, which need further clinical research.
- [1]Stelloo, Ellen,Nout, Remi A.,Osse, Elisabeth M.,etc.Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts[J].2016,22(16).
- [2]Matthews KS,Rocconi RP,Whitworth JM,etc.Lynch syndrome in women less than 50 years of age with endometrial cancer.[J].2008,111(5).
- [3]Gilks, C. Blake,Talhouk, Aline,McAlpine, Jessica N.,etc.Clinical and pathological characterization of endometrial cancer in young women: Identification of a cohort without classical risk factors[J].2015,138(1).
- [4]中国研究型医院学会妇产科专业委员会.早期子宫内膜癌保留生育功能治疗专家共识[J].2019,(4).
- [5]Gad Getz,Stacey B. Gabriel,Kristian Cibulskis,etc.Integrated genomic characterization of endometrial carcinoma[J].2013,497(TN.7447).
- [6]David B. Chapel,S. Diane Yamada,Matthew Cowan,etc.Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens[J].2018,149(3).
- [7]Auguste, Aurelie,Genestie, Catherine,De Bruyn, Marco,etc.Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative[J].2018,31(12).
- [8]Britton, Heidi,Huang, Leo,Lum, Amy,etc.Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma[J].2019,153(3).
- [9]Barakat,Shih K,Garg K.Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.[J].2009,33(12).
- [10]Depreeuw, Jeroen,Stelloo, Ellen,Osse, Elisabeth M.,etc.Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma[J].2017,23(23).
- [11]Michael D, Walsh,Margaret C, Cummings,Daniel D, Buchanan,etc.Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients.[J].2008,14(6).
- [12]Kauff ND,Soslow RA,Barakat RR,etc.Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.[J].2011,123(1).
- [13]Jia, Xu,Douglas I, Lin.Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas.[J].2018,13(7).
- [14]Zakhour, M.,Cohen, J. G.,Gibson, A.,etc.Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series[J].2017,124(10).
- [15]Van Gool, Inge C.,Rayner, Emily,Osse, Elisabeth M.,etc.Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues[J].2018,24(13).
- [16].CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.[J].2017,30(7).
- [17]Talhouk A.,McAlpine J. N..New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care[J].2016,3(1).